To find a reference on this page either scroll or hold down the "Ctrl" key and press "f".
|
tablet splitting
|
| tablet splitting 25(6) 133-5 |
| letters 26(2) 27-9 |
|
tachycardia
|
| adenosine - supraventricular tachycardia - Adenocor (New drug) 18(2) 35-8 |
| ventricular tachycardia - erythromycin terfenadine interactions 18(1) 18 |
| letter 18(2) 27-9 |
|
tacrine
|
| Alzheimer's disease 19(1) 14-7 |
| Alzheimer's disease - Cognex (New formulation) 18(2) 35-8 |
|
tacrolimus
|
| liver transplantation - Prograf (New drug) 21(3) 80-3 |
| letter 22(2) 28-31 |
| pharmacology of immunosuppressants 29(4) 99-101 |
| therapeutic drug monitoring (letter) 20(3) 57-60 |
|
tadalafil
|
| erectile dysfunction - Cialis (New drug) 26(2) 46-7 |
|
TAIS
|
| Therapeutic Advice and Information Service - 23(4) 76-8 |
|
Tamiflu
|
| see oseltamavir 24(2) 43-7 |
|
tamoxifen
|
| breast cancer 21(1) 15-9 |
| compared to toremifene 21(1) 25-7 |
| Tamoxifen-BC (New brand) 24(4) 100-2 |
| women at risk of breast cancer 25(6) 139-41 |
|
tamsulosin hydrochloride
|
| benign prostatic hypertrophy - Flomax (New drug) 23(3) 64-7 |
|
Tarceva
|
| see erlotinib 29(2) 53-5 |
|
Targocid
|
| see teicoplanin 18(1) 7-9 |
|
Tasmar
|
| see tolcapone 21(2) 49-55 |
|
taxanes
|
| breast cancer (PBAC question) 30(1) 24-5 |
|
Taxol
|
| see paclitaxel 17(4) 87-90 |
|
Taxotere
|
| see docetaxel 19(2) 38-40 |
|
tazarotene
|
| Zorac - psoriasis, acne (New drug) 29(3) 84-7 |
|
tazobactam piperacillin combination
|
| Tazocin (New drug) 17(3) 73 |
|
Tazocin
|
| see tazobactam piperacillin 17(3) 73 |
|
technetium scanning
|
| arcitumomab - colorectal cancer immunoscintigraphy - CEA-Scan (New drug) 26(3) 68-71 |
| sulesomab - osteomyelitis diagnosis - LeukoScan (New drug) 25(3) 74-5 |
|
technology, diagnostic
|
| high cost (editorial) 17(3) 54-5 |
| letters 18(2) 27-9 |
|
tegaserod
|
| advertising (editorial comment) 26(3) 67 |
| irritable bowel syndrome - Zelmac (New drug) 25(3) 74-5 |
|
teicoplanin
|
| antibiotic - Targocid (New drug) 18(1) 7-9 |
|
telbivudine
|
| chronic hepatitis B - Sebivo (New drug) 30(6) 163-7 |
|
Telfast
|
| see fexofenadine 20(4) 83-6; 20(2) 45-51 |
|
telmisartan
|
| hypertension - Micardis (New drug) 22(6) 147-51 |
|
Telzir
|
| see fosamprenavir 28(1) 19-23 |
|
temazepam
|
| capsules and injecting drug users 27(3) 58-9 |
| letter 27(5) 109-13 |
| prescription patterns 26(4) 78-81 |
|
Temodal
|
| see temozolomide 23(1) 21-3 |
|
temozolomide
|
| brain tumours - Temodal - (New drug) 23(1) 21-3 |
|
temporomandibular disorders
|
| emergency management of dental pain 24(6) 144-8 |
|
tenecteplase
|
| thrombolysis - Metalyse (New drug) 24(2) 43-7 |
|
tenofovir disoxopril fumarate
|
| Viread (New drug) 25(6) 147-51 |
|
TENS
|
| in back pain - letter 18(1) 4-7 |
|
Tequin
|
| see gatifloxacin 24(3) 71-5 |
|
teratogens - see birth defects
|
|
terazosin
|
| antihypertensive, prostatic hypertrophy - Hytrin (New drug) 18(1) 7-9 |
| prostatic hypertrophy 18(2) 30-2 |
|
terbinafine
|
| in cutaneous fungal infections 19(3) 72-5 |
| and fungal toenails (PBAC question) 22(6) 135 |
| letter 23(4) 72 |
|
terbutaline
|
| in asthma 21(1) 22-4 |
|
terfenadine
|
| erythromycin interactions and ventricular tachycardia 18(1) 18 |
| letter 18(2) 27-9 |
| terfenadine metabolite - fexofenadine - Telfast (New drug) 20(4) 83-6; 20(2) 45-51 |
|
teriparatide
|
| osteoporosis - Forteo (New drug) 27(1) 21-3 |
| letter 27(5) 109-13 |
|
testosterone
|
| Androderm (New formulation) 24(4) 100-2 |
| Androderm (New strength) 25(6) 147-51 |
| erectile dysfunction 21(2) 46-8 |
| fertility testing - abnormal laboratory results 25(2) 38-40 |
| hormone replacement therapy in menopause 17(1) 13-6 |
|
tetanus vaccine
|
| management of animal and human bites 29(1) 6-8 |
|
tetanus, diphtheria and pertussis vaccine
|
| diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b - Infanrix penta, Infanrix hexa and Infanrix IPV (New combinations) 27(6) 159-65 |
| see triple antigen (New brand) 24(4) 100-2 |
|
Teveten
|
| see eprosartan mesylate 25(6) 147-51; 23(4) 84-7 |
|
thalassaemia
|
| deferasirox - Exjade - chelating agent (New drug) 29(4) 112-5 |
| diferiprone - Ferriprox (New drug) 26(3) 68-71 |
| screening (abnormal laboratory results) 24(5) 120-3 |
| letter 25(2) 27-8 |
|
thalidomide
|
| angiogenesis inhibitors in cancer 29(1) 9-12 |
| erythema nodosum leprosum, multiple myeloma - Thalidomide Pharmion (New drug) 26(6) 146-51 |
| tumour necrosis factor blockers in rheumatoid arthritis (letter) 28(1) 5-7 |
|
Thalidomide Pharmion
|
| see thalidomide 26(6) 146-51 |
|
thallium scanning
|
| in coronary disease 17(3) 57-61 |
| expensive medical technology 17(3) 54-5 |
| letters 18(2) 27-9 |
|
Therapeutic Advice and Information Service
|
| TAIS - 26(4) 88-90; 23(4) 76-8 |
|
therapeutic devices
|
| home oxygen therapy 19(3) 69-71 |
| infusion lines in management of anaphylaxis (letter) 19(1) 3-6; 18(3) 56-7 |
| infusion pumps 18(2) 49-51 |
| letter 18(4) 84-6 |
| letter 20(3) 57-60 |
| price of drugs and developing countries (letter) 19(1) 3-6 |
| therapeutic drug monitoring 20(1) 9-11 |
| time taken for evaluations (letter) 19(1) 3-6 |
|
Therapeutic Goods Administration
|
| adverse reaction reporting systems 28(6) 140-2 |
| Australian drug regulatory system 18(3) 69-71 |
| drug evaluation and approval processes 27(6) 156-8 |
| regulation of advertising in Australia 27(5) 124-7 |
| rifampicin and MRSA infections - Orphan Drug Scheme (letter) 29(1) 3-5 |
|
therapeutic guidelines
|
| guidelines for asthma 24(4) 78-9 |
| guiding guidelines into practice (editorial) 24(3) 50-1 |
| turning knowledge into action (editorial) 30(5) 114-5 |
|
Therapeutic Guidelines
|
| antibiotics and endocarditis (letter) 24(3) 51-5 |
| book reviews |
| Analgesic 25(6) 135 |
| Antibiotic 30(3) 73; 26(6) 135; 24(4) 85 |
| Cardiovascular 26(6) 124-5 |
| Dermatology 28(2) 44 |
| Endocrinology 28(3) 58; 24(6) 148 |
| Gastrointestinal 30(2) 46; 26(3) 58 |
| Neurology 30(4) 91; 25(6) 141 |
| Oral and Dental 30(4) 106 |
| Palliative care 29(3) 79; 25(1) 18 |
| Psychotropic 27(2) 50 |
| Respiratory 28(5) 129 |
| Rheumatology 29(5) 124 |
| 'Understanding, influencing and evaluating drug use' 25(3) 65 |
| CD review - Electronic Therapeutic Guidelines 25(3) 53 |
| drug information (editorial) 21(3) 58-9 |
| letters 22(2) 28-31; 22(1) 3-5 |
| PDA review - Mini TG (personal digital assistant version) 29(1) 21 |
|
therapeutic index
|
| pharmacokinetics 18(4) 102-4 |
|
therapeutic range
|
| pharmacokinetics 18(4) 102-4 |
|
thiamine deficiency
|
| management of alcohol dependence (letter) 25(5) 104-7 |
|
thiazide diuretics
|
| in hypertension (editorial) 22(5) 102-3 |
| and osteoporosis 24(3) 65-7 |
| in renal calculi 19(4) 94-7 |
|
thiazolidinediones
|
| drug interactions 24(4) 83-5 |
| pharmacology 27(3) 67-70; 27(3) 70-4 |
| letter 27(6) 138-41 |
| pioglitazone - type 2 diabetes - Actos (New drug) 25(1) 20-3 |
| rosiglitazone - type 2 diabetes - Avandia (New drug) |
|
thienopyridines
|
| warfarin interactions 25(4) 81-5 |
|
thrombin time
|
| abnormal laboratory results 18(2) 38-41 |
|
thrombocythaemia, essential
|
| anagrelide - Agrylin (New drug) 23(2) 45-6 |
|
thrombocytopenia, heparin-associated
|
| lepirudin - Refludan (New drug) 23(4) 84-7 |
|
thromboembolism
|
| abnormal laboratory results 22(3) 63-6 |
| antiplatelet therapy after coronary stents 30(4) 92-96 |
| aspirin dosages in prophylaxis 19(3) 79-81 |
| letter 20(1) 3-4 |
| aspirin vs warfarin in atrial fibrillation 18(3) 72-4 |
| contraceptives, hormone replacement therapy and risk of thrombosis 25(3) 57-9 |
| danaparoid - Orgaran (New drug) 17(3) 73 |
| deep vein thrombosis and air travel 23(5) 107-9 |
| letters 24(5) 107-9; 24(3) 51-5 |
| desirudin - Revasc (New drug) 23(6) 137-9 |
| diagnosis of deep vein thrombosis 21(3) 76-9 |
| letter 22(2) 28-31 |
| diagnosis of recurrent deep venous thrombosis 30(2) 38-40 |
| fondaparinux - Arixtra (New drug) 25(4) 94-9 |
| hormone replacement therapy 23(5) 90-2 |
| low molecular weight heparins 19(4) 104-8 |
| correction 20(1) 20-1 |
| management of post myocardial infarct patients 19(1) 8-10 |
| management of warfarin therapy 24(4) 86-9 |
| letter 24(6) 135-6 |
| nadroparin - Fraxiparine (New drug) 19(2) 38-40 |
| perioperative care of the aged 25(2) 42-4 |
| perioperative management of anticoagulation 23(1) 13-6 |
| prevention of deep vein thrombosis 21(2) 37-9 |
| letter 21(4) 87-91 |
| tinzaparin - Logiparin (New drug) 17(1) 6-8 |
| treatment of deep vein thrombosis 21(3) 64-6 |
| dental implications 21(3) 79 |
| letter 23(4) 72 |
| vascular effects of COX-2 selective inhibitors 27(6) 142-5 |
| letters 28(2) 29-33 |
| warfarin risks and benefits 27(4) 88-92 |
| cataract surgery (letter) 27(6) 138-41 |
|
thrombolytic drugs - see fibrinolytic drugs; anticoagulants
|
|
thrombophilia
|
| abnormal laboratory results 22(3) 63-6 |
|
thromboplastin time
|
| abnormal laboratory results 18(2) 38-41 |
|
Thyrogen
|
| see thyrotropin alfa-rch 24(6) 155-8 |
|
thyroid cancer
|
| diagnosis - thyrotropin alfa-rch 24(6) 155-8 |
|
thyroid disease
|
| iodine in herbal cough mixture (letter) 24(3) 51-5 |
|
thyroid dysfunction
|
| management 17(3) 70-2 |
|
thyroid function tests
|
| abnormal laboratory results in pregnancy 28(4) 98-101 |
| letter 29(1) 3-5 |
|
thyrotropin alfa-rch
|
| thyroid cancer diagnosis - Thyrogen (New drug) 24(6) 155-8 |
|
thyroxine
|
| administration and pharmacokinetics 27(3) 75-6 |
| celery seed tablet interactions 24(1) 6-7 |
| drug interactions 19(2) 47 |
| management of subclinical hypothyroidism 22(6) 132-4 |
| shelf-life and refrigeration (letters) 29(2) 32-5; 28(1) 5-7 |
| in thyroid dysfunction 17(3) 70-2 |
|
tiagabine
|
| in epilepsy 22(3) 61-3 |
| epilepsy - Gabitril (New drug) 21(1) 25-7 |
|
tibolone
|
| postmenopausal symptoms and bone loss - Livial (New drug) 23(4) 84-7 |
|
Ticlohexal
|
| see ticlopidine hydrochloride 23(2) 45-6 |
|
ticlopidine
|
| in antiplatelet therapy 19(4) 98-101 |
| Ticlohexal (New brand) 23(2) 45-6 |
| warfarin interactions 25(4) 81-5 |
|
tigecycline
|
| Tygacil - complicated infections (New drug) 29(5) 138-43 |
|
Tilade
|
| see nedocromil 18(2) 35-8 |
|
Tilade CFC-Free
|
| see nedocromil 24(3) 71-5 |
|
tiludronate
|
| Paget's disease - Skelid (New drug) 21(3) 80-3 |
|
timolol
|
| new formulation - Timoptol-XE 28(3) 75-9; 18(4) 86-7 |
|
timolol/dorzolamide
|
| Cosopt (New combination) 25(4) 94-9 |
|
Timoptol-XE
|
| see timolol 18(4) 86-7 |
|
tinea
|
| antifungal drugs 19(3) 72-5 |
|
tinnitus
|
| Ginkgo biloba (editorial) 29(5) 120 |
| letter 30(2) 32-4 |
|
tinzaparin
|
| low molecular weight heparin - Logiparin (New drug) 17(1) 6-8 |
|
tiotropium bromide
|
| in chronic obstructive pulmonary disease 26(2) 33-5 |
| chronic obstructive pulmonary disease - Spiriva (New drug) 26(1) 22-3 |
|
tipranavir
|
| Aptivus - HIV infection (New drug) 30(4) 107-11 |
|
tirilazad mesylate
|
| aneurysmal subarachnoid haemorrhage - Freedox (New drug) 20(2) 45-51 |
|
tirofiban
|
| in antiplatelet therapy 19(4) 98-101 |
| antiplatelet therapy - Aggrastat (New drug) 22(4) 95-8 |
| warfarin interactions 25(4) 81-5 |
|
Tisseel Duo 500
|
| see fibrin sealant 26(4) 75-7; 26(4) 95; 26(2) 46-7 |
|
tissue adhesives
|
| fibrin sealant - surgical haemostasis - Tisseel Duo 500 (New drug) 26(2) 46-7 |
| correction 26(4) 95 |
| letter 26(4) 75-7 |
|
tolcapone
|
| Parkinson's disease - Tasmar (New drug) 21(2) 49-55 |
|
tolterodine
|
| Detrusitol - overactive bladder (New drug) 28(2) 49-51 |
| overactive bladder 29(1) 22-4 |
| letter 29(4) 91-3 |
|
Tomudex
|
| see raltitrexed 19(4) 108-11 |
|
tooth - see dental, dentistry
|
|
toothpaste
|
| safety 17(2) 49-51 |
| letter 18(1) 4-7 |
|
top 10 drugs
|
| statistics 30(6) 142; 29(6) 167; 29(1) 5; 28(2) 37; 26(6) 140; 26(1) 4; 24(6) 136; 22(5) 119; 21(4) 106; 20(4) 92; 20(1) 17; 19(1) 21; 17(3) 69 |
|
Topamax
|
| see topiramate 23(1) 21-3; 21(3) 80-3 |
|
topical medicines
|
| bruising with miconazole oral gel and warfarin 26(2) 35 |
|
topiramate
|
| in epilepsy 22(3) 61-3 |
| epilepsy - Topamax (New drug) 21(3) 80-3 |
| Topamax (New formulation) 23(1) 21-3 |
|
topotecan
|
| ovarian cancer - Hycamtin (New drug) 20(4) 101-3 |
|
Toprol-XL
|
| see metoprolol succinate 27(3) 76-9 |
|
toremifene
|
| breast cancer - Fareston (New drug) 21(1) 25-7 |
|
torsade de pointes
|
| drugs which prolong the QTC interval 25(3) 63-5 |
|
toxicity
|
| Donnalix Infant Drops (medicinal mishap) 29(3) 83 |
|
toxoplamosis, ocular
|
| management 25(4) 88-90 |
| letter 26(3) 51-2 |
|
Tracleer
|
| see bosentan 26(3) 68-71 |
|
tramadol
|
| adverse effects (editorial) 27(2) 26-7 |
| drug interactions 25(1) 19 |
| and hyponatraemia 27(4) 97 |
| letter 28(2) 29-33 |
| Tramal oral drops (New formulation) 28(6) 156-8 |
| Zydol (New brand) 25(6) 147-51 |
|
Tramal
|
| see tramadol 28(6) 156-8; 21(4) 108-11 |
|
trandolapril
|
| antihypertensive - Odrik (New drug) 17(4) 87-90 |
| Gopten (New formulation) 27(6) 159-65 |
|
tranexamic acid
|
| oral surgery and anticoagulants - letter 26(4) 75-7; 22(1) 3-5 |
|
tranquilising drugs, major - see also antipsychotics
|
| transcutaneous electrical nerve stimulation in back pain (letter) 18(1) 4-7 |
| transferrin - abnormal laboratory results 20(3) 74-6 |
|
transient ischaemic attacks
|
| early management of acute stroke 27(5) 120-3 |
|
transparency of information about new drugs - see drug evaluation, drug regulation
|
|
transplantation - see also specific organs
|
| everolimus - Certican (New drug) 28(3) 75-9 |
| immunosuppressants 29(4) 102-8 |
| stem cell - ancestim - Stemgen (New drug) 23(6) 137-9 |
| letter 24(2) 27-8 |
|
trastuzumab
|
| breast cancer - antineoplastic antibodies 26(6) 141-3 |
| breast cancer - Herceptin (New drug) 24(5) 129-31 |
|
trauma
|
| post-traumatic stress disorder 22(2) 32-4 |
| letters 22(5) 103-5 |
|
Travatan
|
| see travoprost 25(3) 74-5 |
|
travel
|
| chronic disease 23(5) 107-9 |
| deep vein thrombosis (letters) 24(5) 107-9; 24(3) 51-5 |
| malaria prevention 25(3) 66-9 |
| letter 25(6) 131-2; 17(3) 55-6 |
| overseas travel and medicines 29(3) 80-2 |
|
travoprost
|
| in glaucoma 25(6) 142-6 |
| raised intraocular pressure - Travatan (New drug) 25(3) 74-5 |
|
treprostinil
|
| Remodulin - pulmonary arterial hypertension (New drug) 27(6) 159-65 |
|
tretinoin
|
| promyelocytic leukaemia - Vesanoid (New formulation) 19(2) 38-40 |
|
tricyclic antidepressants - see antidepressant drugs
|
|
trigeminal neuralgia
|
| anticonvulsants in neuropathic pain 22(6) 140-1 |
| letter 23(4) 72 |
| patient support organisation 29(3) 75 |
|
Trileptal
|
| see oxcarbazepine 25(4) 94-9; 25(1) 20-3 |
|
trimethoprim with sulphamethoxazole
|
| prescribing statistics 19(2) 47-8 |
|
Triminulet ED
|
| see gestodene ethinyloestradiol combination 18(1) 7-9 |
|
Trioden ED
|
| see gestodene ethinyloestradiol combination 18(1) 7-9 |
|
Tripacel
|
| see triple antigen 21(4) 108-11 |
|
triple antigen
|
| Boostrix (Proprietary brand) 24(4) 100-2 |
| in doctor's bag supplies (PBAC question) 19(3) 75 |
| Infanrix (New drug) 20(2) 45-51 |
| Tripacel (New drug) 21(4) 108-11 |
|
Tritace
|
| see ramipril 24(4) 100-2 |
|
Trizvir
|
| see abacavir/lamivudine/zidovudine combination 24(6) 155-8 |
|
troglitazone
|
| antiemetic in cancer chemotherapy - Navoban (New drug) 17(4) 87-90 |
| type 2 diabetes - Rezulin (New drug) 22(6) 147-51 |
|
troponins
|
| cardiac markers - abnormal laboratory results 26(4) 88-90 |
|
trovafloxacin
|
| antibiotic - Trovan (New drug) 22(2) 43-7 |
|
Trovan
|
| see trovafloxacin 22(2) 43-7 |
|
Trusopt Eye Drops
|
| see dorzolamide 20(2) 45-51 |
|
tuberculosis
|
| BCG vaccination 26(6) 144-6; 26(6) 146 |
| letters 27(2) 28-33 |
|
tuberculosis, pulmonary
|
| isoniazid - in human milk (letter) 21(1) 5-8 |
| rifabutin - Mycobutin (New drug) 17(4) 87-90 |
|
tumour necrosis factor
|
| monoclonal antibodies 29(5) 130-3 |
|
tumour necrosis factor blockers
|
| etanercept - rheumatoid arthritis - Enbrel (New drug) 25(1) 20-3 |
| rheumatoid arthritis 29(3) 67-70; 27(2) 43-6 |
| letter 28(1) 5-7 |
|
tumour necrosis factor inhibitors - see tumour necrosis factor blockers
|
|
Tygacil
|
| see tigecycline 29(5) 138-43 |
|
Tykerb
|
| see lapatinib 30(5) 133-5 |
|
Typherix
|
| see Salmonella typhi Vi 23(1) 21-3 |
|
Typhim Vi
|
| see capsular polysaccharide typhoid vaccine 17(2) 30-2 |
|
typhoid
|
| capsular polysaccharide vaccine - Typhim Vi 17(2) 30-2 |
|
tyramine, dietary
|
| interactions with MAO inhibitors (letters) 17(2) 28-9 |
|
tyrosine kinase inhibitors
|
| dasatinib - Sprycel - chronic myeloid and acute lymphoblastic leukaemia (New drug) 30(2) 50-55 |
| gefitinib - lung cancer - Iressa (New drug) 26(4) 94-5 |
| imatinib - chronic myeloid leukaemia - Glivec (New drug) 24(5) 129-31 |
| lapatinib - breast cancer - Tykerb (New drug) 30(5) 133-5 |
| renal cell cancer 29(6) 151-3 |
| sorafenib - Nexavar - renal cell cancer (New drug) 29(6) 167-71 |
| sunitinib - Sutent - gastrointestinal stromal tumour, renal cell cancer (New drug) 29(6) 167-71 |
|
Tysabri
|
| see natalizumab 30(4) 107-11 |
Home
